Lichen planus and lichenoid dermatoses: Conventional and emerging therapeutic strategies

J Am Acad Dermatol. 2018 Nov;79(5):807-818. doi: 10.1016/j.jaad.2018.02.013.


Having reviewed the diverse clinical subtypes of lichenoid disease and the postulated molecular basis thereof in the first article in this 2-part continuing medical education series, we discuss herein the existing and emerging treatment strategies in the most common clinical forms of lichenoid inflammation and provide an overview of their pharmacodynamics and evidence base. The scope of this review is not to exhaustively discuss treatment modalities for all lichenoid variants discussed in the previous article of this series. Instead, the focus will be on frequently encountered subtypes of lichen planus and on linking mechanisms of disease with mechanisms of drug action. Future directions and potential avenues for translational research will also be discussed.

Keywords: emerging drugs for lichenoid inflammation; lichen planus therapeutics; lichenoid variant therapeutics.

Publication types

  • Review

MeSH terms

  • Administration, Topical
  • Adrenal Cortex Hormones / administration & dosage*
  • Calcineurin Inhibitors / administration & dosage
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Lichen Planus / diagnosis*
  • Lichen Planus / therapy*
  • Lichen Planus, Oral / diagnosis
  • Lichen Planus, Oral / therapy
  • Lichenoid Eruptions / diagnosis
  • Lichenoid Eruptions / therapy
  • Male
  • Phototherapy / methods
  • Prognosis
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome


  • Adrenal Cortex Hormones
  • Calcineurin Inhibitors
  • Immunosuppressive Agents